Dried Blood Spot (DBS) sampling is a microsampling technique used throughout the World for neonatal screening. The work set out in this thesis shows the development and implementation of DBS in the area of preclinical and clinical pharmaceutical drug development, specifically in support of Toxicokinetics and Pharmacokinetics. The advantages of the technique are explored along with the issues faced. The papers discussed in this commentary, include in papers 1 and 2, the concept of supporting both Toxicokinetics and Pharmacokinetics studies and the validation of bioanalytical assays utilising DBS. Commentary paper 3 further explores the practicalities of DBS in the Clinical environment and commentary paper 4 the transferability of DBS technology between laboratories. Commentary paper 5 uses Incurred Sample Reanalysis data to answer questions around specific DBS issues and commentary paper 6 looks at indicating papers for Dried Plasma Spots. Commentary papers 7 and 8 explore the use of consortia to investigate hematocrit and homogeneity when using DBS and finally commentary paper 9 explores the training required to ensure quality DBS samples. The impact and contributions to this field of research are demonstrated through discussion and critical examination of selected examples of the author’s peerreviewed publications in this area. Developments of scientific practices, where the author has contributed intellectual, leadership and practical insight to achieve significant improvements in the generation of knowledge, are highlighted throughout the commentary.